包装 | 价格(元) |
10mM (in 1mL DMSO) | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
Cell lines | CD34+UCB cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Reaction Conditions | 1 μM, 3 weeks |
Applications | CD34+UCB cells were cultured for 3 weeks with 1μM SR1 or 0.01% DMSO (control). Total cell number was determined at day 7, 14, and 21 and the frequency of pDCs was evaluated at each time point by flow cytometry. During the 3-weeks culture period the total nucleated cells continuously expanded. Analysis of pDC differentiation in time revealed that the maximum frequency of pDCs was already reached at day 14. However, the absolute number of pDCs was highest on day 21. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
产品描述 | StemRegenin 1 (SR1), a purine derivative, is a potent small molecule inhibitor of aryl hydrocarbon receptor (AhR) that potently antagonizes AhR with a value of 50% inhibition concentration IC50of 127 nM in CD34+cells. SR1 has been found to promote the ex vivo expansion of CD34+cells. Recent study results have suggested that culture of hematopoietic stem cells (HSC) with SR1 increases cells expressing CD34 by fifty-fold and increases cells retaining the ability to engraft immunodeficient mice by 17-fold. SR1 has also been found to induce the ex vivo differentiation of pDCs, BDCA1+and BDCA3+mDCs as well as the generation of high numbers of all these DC subsets. Reference [1].Thordardottir S, Hangalapura BN, Hutten T, Cossu M, Spanholtz J, Schaap N, Radstake TR, Vandervoort R, Dolstra H. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem Cells Dev. 2013 Dec 10. [Epub ahead of print] |